According to a decision by the Annual General Meeting on April 26, 2021, new principles for appointment of the Nomination Committee's members and instructions for the Nomination Committee were adopted.

This means that BICO Group AB (BICO) shall have a nomination committee consisting of five members, one of whom shall be the Chairman of the Board. Other members shall be appointed by the four largest shareholders in the company as of the end of September, on the basis of a list of registered shareholders provided by Euroclear Sweden AB and other reliable information that has been available to the company.

The following have been appointed to be part of BICO's Nomination Committee in preparation for the 2022 Annual General Meeting:

  • Mats Engström, nominated by Erik Gatenholm
  • Claes Dinkelspiel, nominated by Héctor Martínez
  • Malin Björkmo, nominated by Handelsbanken Fonder
  • Jan Dworsky, nominated by Swedbank Robur Fonder
  • Carsten Browall, Chairman of the Board of BICO Group AB

The Annual General Meeting of BICO Group AB will be held at 5pm on April 26, 2022 in Gothenburg. Shareholders who wish to submit proposals to BICO's Nomination Committee can do so via e-mail to: ir@bico.com (“To the Nomination Committee”) or letter to: BICO Group AB, Att: The Nomination Committee, Arvid Wallgrens backe 20, 413 46 Gothenburg, no later than January 31, 2022.

For further information, please contact:

Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
Email:
il@bico.com

This information was submitted for publication, through the agency of the contact person set out above, on October 8, 2021, at 15:00 (CEST).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading Bio Convergence company in the world by combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com